UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

The New England journal of medicine, 2012-07, Vol.367 (2), p.107-114

2012

Link zum Volltext

Verfügbarkeit prüfen

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

The lancet oncology, 2016-09, Vol.17 (9), p.1317-1324

2016

Link zum Volltext

Verfügbarkeit prüfen

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Cancer Immunology, Immunotherapy, 2014-05, Vol.63 (5), p.449-458

2014

Link zum Volltext

Verfügbarkeit prüfen

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Journal of clinical oncology, 2021-08, Vol.39 (24), p.2656-2666

2021

Link zum Volltext

Verfügbarkeit prüfen

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Journal of clinical oncology, 2021-03, Vol.39 (9), p.1020-1028

2021

Link zum Volltext

Verfügbarkeit prüfen

Translational implications of tumor heterogeneity

Clinical cancer research, 2015-03, Vol.21 (6), p.1258-1266

2015

Link zum Volltext

Verfügbarkeit prüfen

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

European journal of cancer (1990), 2022-11, Vol.176, p.121-132

2022

Link zum Volltext

Verfügbarkeit prüfen

Galactic-scale Feedback Observed in the 3C 298 Quasar Host Galaxy

The Astrophysical journal, 2017-12, Vol.851 (2), p.126

2017

Link zum Volltext

Verfügbarkeit prüfen

Imaging of translocator protein upregulation is selective for pro‐inflammatory polarized astrocytes and microglia

Glia, 2020-02, Vol.68 (2), p.280-297

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging

Cancer research (Chicago, Ill.), 2019-04, Vol.79 (7), p.1343-1352

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Journal of clinical oncology, 2023-05, Vol.41 (14), p.2493-2502

2023

Link zum Volltext

Verfügbarkeit prüfen

Boronic Acid Resin for Selective Immobilization of Canonically Encoded Proteins

Biomacromolecules, 2023-05, Vol.24 (5), p.2196-2202

2023

Link zum Volltext

Verfügbarkeit prüfen

Dynamical Constraints on the HR 8799 Planets with GPI

The Astronomical journal, 2018-11, Vol.156 (5), p.192

2018

Link zum Volltext

Verfügbarkeit prüfen

Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal

Scientific reports, 2019-05, Vol.9 (1), p.7889, Article 7889

2019

Link zum Volltext

Verfügbarkeit prüfen

A Spatially Resolved Survey of Distant Quasar Host Galaxies. I. Dynamics of Galactic Outflows

The Astrophysical journal, 2021-10, Vol.919 (2), p.122

2021

Link zum Volltext

Verfügbarkeit prüfen

IROCKS: SPATIALLY RESOLVED KINEMATICS OF z ∼ 1 STAR-FORMING GALAXIES

The Astrophysical journal, 2016-11, Vol.831 (1), p.78

2016

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

European journal of cancer (1990), 2008-10, Vol.44 (15), p.2152-2161

2008

Link zum Volltext

Verfügbarkeit prüfen

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

The lancet oncology, 2015-11, Vol.16 (15), p.1473-1482

2015

Link zum Volltext

Verfügbarkeit prüfen

STAT3-Mediated Astrocyte Reactivity Associated with Brain Metastasis Contributes to Neurovascular Dysfunction

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5642-5655

2020

Link zum Volltext

Verfügbarkeit prüfen

Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

Expert opinion on pharmacotherapy, 2017-09, Vol.18 (14), p.1477-1490

2017

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The lancet oncology, 2015-04, Vol.16 (4), p.375-384

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.284

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.155)
Mit Volltextzugriff
(1.140)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.280)
Japanisch
(99)
Russisch
(3)
Deutsch
(1)
Spanisch
(1)
Norwegisch
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(147)
The Astrophysical Journal
(43)
The Lancet Oncology
(40)
European Journal Of Cancer
(36)
The Astronomical Journal
(28)
The New England Journal Of Medicine
(28)
Cancer Research
(23)
Clinical Cancer Research
(18)
Blood
(14)
Plos One
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Translational implications of tumor heterogeneity

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

Galactic-scale Feedback Observed in the 3C 298 Quasar Host Galaxy

Imaging of translocator protein upregulation is selective for pro‐inflammatory polarized astrocytes and microglia

Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

Boronic Acid Resin for Selective Immobilization of Canonically Encoded Proteins

Dynamical Constraints on the HR 8799 Planets with GPI

Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

A Spatially Resolved Survey of Distant Quasar Host Galaxies. I. Dynamics of Galactic Outflows

IROCKS: SPATIALLY RESOLVED KINEMATICS OF z ∼ 1 STAR-FORMING GALAXIES

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

STAT3-Mediated Astrocyte Reactivity Associated with Brain Metastasis Contributes to Neurovascular Dysfunction

Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Suchergebnisse filtern